Tebentafusp improves OS in advanced uveal melanoma

Source: Healio, April 2021

Tebentafusp significantly prolonged OS compared with immune checkpoint inhibitors and other standard therapies among previously untreated patients with metastatic uveal melanoma, results of a randomized phase 3 study showed.

The investigational bispecific fusion protein also had a manageable safety profile, according to the findings, presented during the virtual American Association for Cancer Research Annual Meeting.

READ THE ORIGINAL FULL ARTICLE